{
    "cancer_info": {
        "cancer_name": "Small Cell Lung Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Biopsy/cytology of primary/metastatic site",
            "History & Physical (H&P)",
            "Complete blood count (CBC)",
            "Electrolytes",
            "Liver function tests (LFTs)",
            "Blood urea nitrogen (BUN) and creatinine",
            "Contrast-enhanced CT of chest, abdomen, and pelvis",
            "Brain MRI (preferred) or contrast CT if MRI contraindicated",
            "FDG-PET/CT (skull base to mid-thigh)",
            "Bone scan (if PET unavailable)",
            "Thoracentesis (for pleural effusion)",
            "Bone imaging or MRI (if PET equivocal for bone metastases)",
            "Bone marrow biopsy (if cytopenias or nucleated RBCs)",
            "Pathology review with immunohistochemistry: Neuroendocrine markers (INSM1, CD56, synaptophysin, chromogranin A)",
            "POU2F3 IHC if neuroendocrine markers negative",
            "Ki-67 testing",
            "Comprehensive molecular profiling (for relapsed extensive-stage SCLC in never/light smokers)",
            "Pulmonary function tests",
            "EBUS-TBNA for nodal staging",
            "Mediastinoscopy for clinical stage I-IIIA",
            "Thoracoscopy for cytologically negative pleural effusions",
            "Hyponatremia screening (for SIADH)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Limited Stage (T1-4 N0-3 M0)",
            "risk_group": "PS 0-2",
            "treatment_plans": [
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "General",
                    "plan_name": "Concurrent chemoradiation",
                    "plan_details": "Cisplatin/etoposide + thoracic RT: 45 Gy twice daily over 3 weeks or 66-70 Gy once daily over 6-7 weeks",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Category 1"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "T1-2 N0 M0",
                    "plan_name": "Surgery",
                    "plan_details": "Lobectomy + mediastinal lymph node dissection",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Primary Therapy",
                    "patient_subgroup": "Medically inoperable T1-2 N0",
                    "plan_name": "Stereotactic Ablative RT (SABR)",
                    "plan_details": "50-60 Gy in 3-8 fractions + adjuvant chemotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "After chemoradiation without progression",
                    "plan_name": "Durvalumab consolidation",
                    "plan_details": "1500 mg every 28 days for up to 24 months",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Category 1"
                },
                {
                    "treatment_line": "Adjuvant Therapy",
                    "patient_subgroup": "Post-surgery with node-positive disease",
                    "plan_name": "Post-operative RT",
                    "plan_details": "Radiation therapy to mediastinum",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Prophylactic Therapy",
                    "patient_subgroup": "Complete/partial response after primary therapy",
                    "plan_name": "Prophylactic Cranial Irradiation (PCI)",
                    "plan_details": "25 Gy in 10 fractions with hippocampal avoidance considered",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Category 1"
                }
            ]
        },
        {
            "staging_criteria": "Limited Stage (T1-4 N0-3 M0)",
            "risk_group": "PS 3-4",
            "treatment_plans": [
                {
                    "treatment_line": "Supportive Care",
                    "patient_subgroup": "General",
                    "plan_name": "Individualized therapy",
                    "plan_details": "Supportive care ± palliative radiotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                }
            ]
        },
        {
            "staging_criteria": "Extensive Stage (M1)",
            "risk_group": "PS 0-2",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "Platinum/etoposide + PD-L1 inhibitor",
                    "plan_details": "Atezolizumab or durvalumab with carboplatin/cisplatin and etoposide",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Category 1"
                },
                {
                    "treatment_line": "Consolidation Therapy",
                    "patient_subgroup": "Responders with residual thoracic disease",
                    "plan_name": "Thoracic RT",
                    "plan_details": "30 Gy in 10 fractions",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Prophylactic Therapy",
                    "patient_subgroup": "Responders",
                    "plan_name": "Prophylactic Cranial Irradiation (PCI)",
                    "plan_details": "20-25 Gy in 5-10 fractions (optional with hippocampal avoidance)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Subsequent Therapy",
                    "patient_subgroup": "CTFI ≥6 months (Sensitive relapse)",
                    "plan_name": "Lurbinectedin or Tarlatamab",
                    "plan_details": "Lurbinectedin OR Tarlatamab-dlle (DLL3-targeted bispecific antibody)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Subsequent Therapy",
                    "patient_subgroup": "CTFI <6 months (Refractory disease)",
                    "plan_name": "Topotecan or CAV regimen",
                    "plan_details": "Topotecan (IV/oral) OR Cyclophosphamide/Doxorubicin/Vincristine (CAV)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                },
                {
                    "treatment_line": "Palliative Therapy",
                    "patient_subgroup": "Symptomatic metastases",
                    "plan_name": "Site-directed RT",
                    "plan_details": "Bone mets: 8 Gy single fraction; Brain mets: SRS for 1-4 lesions or WBRT (30 Gy/10 fractions)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                }
            ]
        },
        {
            "staging_criteria": "Extensive Stage (M1)",
            "risk_group": "PS 3-4",
            "treatment_plans": [
                {
                    "treatment_line": "Supportive Care",
                    "patient_subgroup": "General",
                    "plan_name": "Palliative therapy",
                    "plan_details": "Supportive care ± palliative RT to symptomatic sites",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Category 2A"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Neuroendocrine markers (INSM1, CD56, synaptophysin, chromogranin A): Define SCLC diagnosis; POU2F3: Identifies neuroendocrine-low subtypes; DLL3: Target for tarlatamab therapy in relapsed disease (expressed in 85-94% of SCLC); MGMT Methylation: Predicts response to temozolomide in relapsed SCLC; Genomic profiling: Identifies potential actionable targets in relapsed ES-SCLC (especially in never/light smokers)"
    },
    "guideline_id": "（2025.V3）NCCN临床实践指南：小细胞肺癌.txt"
}